This story detailed the long-term outcomes at one institution for obese individuals who had gastric banding surgery. The story was clear about the drawbacks inherent in the study. For example, that the data were obtained from a relatively small number of patients, and these patients, by virtue of the time at which they had the surgery performed, may differ somewhat from the results in current patients. The story also presented information useful for setting up realistic expectations about the long-term benefits and potential harms of gastric banding. As more people consider the available options for assisting in obesity management, the information about the amount of weight lost and the lackluster impact on weight-related health conditions, such as type 2 diabetes, hypertension, and sleep apnea, this story serves as an important counterbalance to the direct-to-consumer advertising on the procedure.
Obesity is a significant public health issue and impacts up to one third of American adults. Diet and exercise are still the preferred approach. Drug therapy for obesity remains elusive as evidenced by the recent refusal of the FDA to approve Qnexa. Increasingly, people with morbid obesity are turning to surgical treatments. Patients have two choices in this regard. The standard gastric bypass or placement of an adjustable band around the stomach opening. Both approaches are deemed safe. While the banding approach is simpler and carries fewer immediate risks, the weight loss is not as great as with the bypass procedure. This new study adds to our understanding of the longstanding outcomes of a group of patients who received an earlier generation banding device.
As with the HealthDay story we reviewed, there was no discussion of costs of the banding procedure nor for regular office visits for band adjustment. Although these costs were not detailed in the study reported on, this information is readily available. We think that this is unfortunate given the magnitude of the cost of the procedure. We also would have liked to have seen a comment or two about insurance coverage
The only benefit reported on in this story was the average loss of excess weight experienced by those who had had the procedure and in those who still had their Lap-Bands at the end of the study period.
The story did a good job providing information about the common harms, along with the percentage of individuals affected.
The story did not engage in overt disease-mongering.
The story included interview comments from a company spokesperson and one of the authors of the study, both of whom were clearly identified. The story also included this important detail about the quoted author, which was missed by the HealthDay story we reviewed. “Himpens reports consultant work for Ethicon Endosurgery, which makes another gastric band, Realize, and for Covidien, a health care products company.” In addition, the story had comments from two surgeons who do not appear to have direct ties with either the manufacturer of the product or the study reported on. We were a little concerned about some of the phrasing in the story. It says, “But some, including the manufacturer of the Lap-Band — used in a technique called laparoscopic adjustable gastric banding — take exception to the study, criticizing the small sample size and the number of patients lost to follow-up.The critics also point out that both the device itself and the expertise of surgeons placing it have improved greatly since the patients in the study had their bands placed, in the years 1994 through 1997.” This leads readers to believe that there are mulitple critics out there pointing out flaws in the study. The story itself, though, only quotes one actual critic: the company spokewoman. The criticisms may be valid, but readers deserved a strong independent analysis of the study’s limitations.
While the story did mention at the very end how the pace of weight loss with the product reported on compared with weight loss following gastric bypass surgery, the story ought to have provided better insight about the long-term outcomes in those who have gastric bypass and those who chose not to have surgery to help manage their excess weight. That way, readers could compare the two commonly utilized surgical options and understand the differences between them. The story hints at this by paraphrasing a study author saying that Lap-Band patients, “may have less weight loss and more complications than those who choose other weight loss surgeries.” But it never provides any evidence to back that claim. We also would have liked to have seen some comment about diet and exercise.
The story makes it clear that the gastric banding procedure is available and provides a link to information from the National Institutes of Health.
The story was clear that it was not reporting on a new or novel treatment but rather was reporting on the long-term outcomes presented in a recent research paper.
This story does not appear to be based exclusively on a news release.
Systematic, Criteria-Driven
Puleeeeease... this 'game changer' weight loss drug causes more nausea and vomiting than a placebo. Some game, some change. My friend Gary would spank you for using the eighth word medical reporters should never, ever use. @garyschwitzer @thackerpd
https://www.healthnewsreview.org/toolkit/just-journalists-writing-tips-case-studies/7-words-and-more-you-shouldnt-use-in-medical-news/ https://twitter.com/OttawaCitizen/status/1361426796126830597
A scary @statnews Op-Ed warns that govt attempts to rein in Pharma may cut off access to "life-changing" drugs.
It takes @garyschwitzer to let us know: the author spent 10 years as Pfizer's public-policy chief. https://twitter.com/garyschwitzer/status/1360325022578053123
.@TranspariMED criticizes STAT op-ed for not disclosing pharma funding of author’s institute - similar to criticism we’ve made of STAT op-eds in the past. @transparify @ThinkTankWatch @icer_review https://www.healthnewsreview.org/2021/02/transparency-watchdog-criticizes-stats-non-disclosure-on-pro-pharma-op-ed/
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like